How This Evidence Evolved
OCT in Retinal Disease
From fluorescein angiography to AI-enhanced optical coherence tomography
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Mean visual-acuity change at one year
Sensitivity and specificity for glaucoma detection
Visual acuity change at month 12: monthly 9.2 vs treat-and-extend 10.5 letters (P=0.60); mean injections 13.0 vs 10.1 (P<0.0001).
Visual acuity at 1 year: monthly bevacizumab +8.0 versus ranibizumab +8.5 letters; as-needed +5.9 versus +6.8. Serious systemic adverse events 24.1% versus 19.0% by drug (RR 1.29, 95% CI 1.01–1.66).
Follow-up studies, subgroup analyses, and real-world validation
Current standard of care and ongoing research directions
14 of 40 eligible participants initiated scanning; 86.5% of 2304 scans were eligible for fluid quantification.
Review of non-OCT home monitoring, including ForeseeHome, and home OCT for retinal disease.
Landmark Trials in This Story
Optical coherence tomography
Demonstration of in vitro OCT imaging
Reproducibility of nerve fiber layer thickness measurements using optical coherence tomography.
RNFL reproducibility over 1 month.
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
Mean visual-acuity change at one year
Comparison of glaucoma diagnostic Capabilities of Cirrus HD and Stratus optical coherence tomography
Sensitivity and specificity for glaucoma detection
Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results.
Visual acuity change at month 12: monthly 9.2 vs treat-and-extend 10.5 letters (P=0.60); mean injections 13.0 vs 10.1 (P<0.0001).
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
Visual acuity at 1 year: monthly bevacizumab +8.0 versus ranibizumab +8.5 letters; as-needed +5.9 versus +6.8. Serious systemic adverse events 24.1% versus 19.0% by drug (RR 1.29, 95% CI 1.01–1.66).
Clinically applicable deep learning for diagnosis and referral in retinal disease
Referral recommendation performance relative to experts
Optical coherence tomography angiography
Clinical utility of OCTA across retinal vascular diseases
Home OCT Imaging for Newly Diagnosed Neovascular Age-Related Macular Degeneration: A Feasibility Study.
14 of 40 eligible participants initiated scanning; 86.5% of 2304 scans were eligible for fluid quantification.
Use of Home Optical Coherence Tomography for Retinal Diseases.
Review of non-OCT home monitoring, including ForeseeHome, and home OCT for retinal disease.
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.